Collagen News and Research

Latest Collagen News and Research

DePuy Synthes CMF introduces SYNTHECEL Dura Repair for use in neurosurgery

DePuy Synthes CMF today announced the launch of SYNTHECEL Dura Repair, the first commercially available biosynthesized dural replacement derived from cellulose for use in neurosurgery. DePuy Synthes CMF is a part of the DePuy Synthes Companies of Johnson & Johnson.

7 May 2015

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that activity and tolerance data for its second lead product Col-Treg were presented through a poster presentation at the 2015 ARVO Annual Meeting, May 3-7, 2015, in Denver, Colorado, US.

5 May 2015

Scientists grow miniature human myelomas in shell-less chicken eggs to study multiple myeloma

Multiple myeloma is an incurable cancer of the bone marrow. To date, no screening systems have been available to examine the effects of new drugs in a 3D environment. Researchers on the EU project OPTATIO might now fill this gap. They succeeded in growing miniature human myelomas in shell-less chicken eggs in order to screen new marine compounds for anti-myeloma activity.

5 May 2015

Advances in thoracic surgery: an interview with Dan Wildman, VP Global Franchise Strategy & Innovation- Ethicon

Without a doubt, one of the most significant developments in thoracic surgery was the advent of video-assisted thoracoscopic surgery or VATS in the 1990s...

22 Apr 2015

Researchers discover molecular mechanism that links breast tissue stiffness to tumor metastasis

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have discovered a molecular mechanism that connects breast tissue stiffness to tumor metastasis and poor prognosis. The study, published April 20 in Nature Cell Biology, may inspire new approaches to predicting patient outcomes and halting tumor metastasis.

21 Apr 2015

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).

20 Apr 2015

TGen scientists discover the likely cause of rare type of muscle weakness in six children

Scientists at the Translational Genomics Research Institute (TGen), using state-of-the-art genetic technology, have discovered the likely cause of a child's rare type of severe muscle weakness.

10 Apr 2015

Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) and Cellular Dynamics International, Inc. (CEO: Robert J. Palay), a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that the two companies have entered into a definitive agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger.

30 Mar 2015

Experimental nanoparticle therapy speeds healing of all sorts of wounds

An experimental therapy developed by researchers at Albert Einstein College of Medicine of Yeshiva University cut in half the time it takes to heal wounds compared to no treatment at all. Details of the therapy, which was successfully tested in mice, were published online in the Journal of Investigative Dermatology.

30 Mar 2015

UAB scientist explores the bone development function of runx2 gene

Amjad Javed, Ph.D., of the University of Alabama at Birmingham, has taken a major step forward in understanding the bone development function of a gene called runx2, which could lead to future ways to speed bone healing, aid bone bioengineering, stem osteoporosis and reduce arthritis.

30 Mar 2015

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

25 Mar 2015

Plexin D1 gene determines body fat distribution in humans

Scientists have known for some time that people who carry a lot of weight around their bellies are more likely to develop diabetes and heart disease than those who have bigger hips and thighs.

24 Mar 2015

Researchers identify promising new approach to treat pulmonary fibrosis

By uncovering the mechanism by which fibrous tissue cells in the lung multiply, researchers at The Saban Research Institute of Children's Hospital Los Angeles, along with colleagues in Mexico and Canada, have identified a promising new approach for the treatment of pulmonary fibrosis.

18 Mar 2015

New strategy may ensure safety of adult epidermal stem cells before performing treatments

A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected and cultivated, genetically modified and single cells isolated before being rigorously tested to make sure they meet the highest possible safety criteria.

28 Feb 2015

Targeting stroma could potentially extend survival of pancreatic cancer patients

Like a stealth jet cloaks itself from radar, cancer cells cloak themselves within tumors by hiding behind a dense layer of cellular material known as stroma.

27 Feb 2015

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the submission of a Clinical Trial Application (CTA) to the German Competent Authority, the Paul-Ehrlich-Institut (PEI), requesting clearance to initiate a Phase 1 clinical trial investigating the use of RCS-01 to treat patients suffering from aged and UV-damaged skin.

23 Feb 2015

MD Anderson awarded more than $22 million in research grants from CPRIT

The University of Texas MD Anderson Cancer Center has received more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas. Approximately half of the funds awarded for Individual Investigator Research Awards went to MD Anderson faculty as well as 40 percent of total IIRA awards that include those for children's and adolescent cancer and early detection and prevention.

21 Feb 2015

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Nanometer-sized "drones" that deliver a special type of healing molecule to fat deposits in arteries could become a new way to prevent heart attacks caused by atherosclerosis, according to a study in pre-clinical models by scientists at Brigham and Women's Hospital and Columbia University Medical Center.

19 Feb 2015

Researchers report development of first 3D tissue-engineered system

A team led by researchers at Tufts University School of Engineering and the University of Pavia has reported development of the first three-dimensional tissue system that reproduces the complex structure and physiology of human bone marrow and successfully generates functional human platelets.

19 Feb 2015

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2014, including a summary of recent corporate highlights.

19 Feb 2015

Collagen News and Research

Latest Collagen News and Research

DePuy Synthes CMF introduces SYNTHECEL Dura Repair for use in neurosurgery

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

Scientists grow miniature human myelomas in shell-less chicken eggs to study multiple myeloma

Advances in thoracic surgery: an interview with Dan Wildman, VP Global Franchise Strategy & Innovation- Ethicon

Researchers discover molecular mechanism that links breast tissue stiffness to tumor metastasis

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

TGen scientists discover the likely cause of rare type of muscle weakness in six children

Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

Experimental nanoparticle therapy speeds healing of all sorts of wounds

UAB scientist explores the bone development function of runx2 gene

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Plexin D1 gene determines body fat distribution in humans

Researchers identify promising new approach to treat pulmonary fibrosis

New strategy may ensure safety of adult epidermal stem cells before performing treatments

Targeting stroma could potentially extend survival of pancreatic cancer patients

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

MD Anderson awarded more than $22 million in research grants from CPRIT

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Researchers report development of first 3D tissue-engineered system

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Collagen News and Research

Latest Collagen News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in